This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population | MicrobiomeTrials
← Back to trials NCT06096909
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-11-11Est. Completion: 2028-03-01
Enrollment target: 3,684 participantsLocations Fuwai Hospital, Beijing, Beijing Municipality, China Tangshan Central Hospital, Tangshan, Hebei, China Other microbiome trials you might be interested in Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) Acute Coronary Syndromes ST-segment Elevation Myocardial Infarction (STEMI) Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
This study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in c…
Beijing, China Completed Mar 8, 2026
B Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…
Birmingham, United States Est. completion Dec 1, 2030
Acute Coronary Syndromes (ACS)
This study aims to find out whether reduced everyday functioning before the acute illness and malnutrition help predict …
Samara, Russia Est. completion Jan 2029